Roche stops crenezumab trials in early Alzheimer’s for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback Wednesday after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc. unit has rights to the anti-β amyloid mAb from AC Immune S.A. (NASDAQ:ACIU), which lost $7.08 (66%) to $3.65 on

Read the full 537 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE